ProQR Therapeutics NV
NASDAQ:PRQR
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
ProQR Therapeutics NV
NASDAQ:PRQR
|
NL |
|
Red Cat Holdings Inc
NASDAQ:RCAT
|
PR |
|
F
|
Fusion Micro Finance Ltd
NSE:FUSION
|
IN |
|
Melhus Sparebank
OSE:MELG
|
NO |
|
K
|
Kaap Agri Ltd
JSE:KAL
|
ZA |
|
L
|
Lepu Scientech Medical Technology Shanghai Co Ltd
HKEX:2291
|
CN |
|
Dolphin Capital Investors Ltd
LSE:DCI
|
VG |
|
P
|
Paragon Union Bhd
KLSE:PGLOBE
|
MY |
|
N
|
Nalwa Sons Investments Ltd
NSE:NSIL
|
IN |
Wall Street
Price Targets
PRQR Price Targets Summary
ProQR Therapeutics NV
According to Wall Street analysts, the average 1-year price target for
PRQR
is 8.8 USD
with a low forecast of 4.04 USD and a high forecast of 14.7 USD.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is PRQR's stock price target?
Price Target
8.8
USD
According to Wall Street analysts, the average 1-year price target for
PRQR
is 8.8 USD
with a low forecast of 4.04 USD and a high forecast of 14.7 USD.
What is ProQR Therapeutics NV's Revenue forecast?
Projected CAGR
44%
For the last 12 years the
compound annual growth rate for
ProQR Therapeutics NV's revenue is
51%.
The projected
CAGR
for the next 3 years is
44%.
